Citadel J Cabasag1, Melina Arnold2, Mark Rutherford3, Aude Bardot2, Jacques Ferlay2, Eileen Morgan2, Alana Little4, Prithwish De5, Elijah Dixon6, Ryan R Woods7, Nathalie Saint-Jacques8, Sue Evans9, Gerda Engholm10, Mark Elwood11, Neil Merrett12, David Ransom13, Dianne L O'Connell14, Freddie Bray2, Isabelle Soerjomataram2. 1. Cancer Surveillance Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France. CabasagC@fellows.iarc.fr. 2. Cancer Surveillance Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France. 3. Biostatistics Research Group, Department of Health Sciences, University of Leicester, University Road, Leicester, UK. 4. Cancer Institute New South Wales, Sydney, NSW, Australia. 5. Surveillance and Cancer Registry, Ontario Health (Cancer Care Ontario), Toronto, ON, Canada. 6. Department of Surgery, University of Calgary, Calgary, AB, Canada. 7. Cancer Control Research, BC Cancer, Vancouver, BC, Canada. 8. Nova Scotia Health Cancer Care Program, Registry & Analytics, Halifax, NS, Canada. 9. Victorian Cancer Registry Division, Cancer Council Victoria, Melbourne, VIC, Australia. 10. Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Society Research Center, Strandboulevarden, Copenhagen, Denmark. 11. School of Population Health, University of Auckland, Auckland, New Zealand. 12. Department of Upper Gastrointestinal Surgery, Bankstown-Lidcombe Hospital and School of Medicine, Western Sydney University, Sydney, NSW, Australia. 13. Fiona Stanley Hospital and Western Australian Department of Health, Perth, WA, Australia. 14. The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia.
Abstract
BACKGROUND: The global burden of pancreatic cancer has steadily increased, while the prognosis after pancreatic cancer diagnosis remains poor. This study aims to compare the stage- and age-specific pancreatic cancer net survival (NS) for seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. METHODS: The study included over 35,000 pancreatic cancer cases diagnosed during 2012-2014, followed through 31 December 2015. The stage- and age-specific NS were calculated using the Pohar-Perme estimator. RESULTS: Pancreatic cancer survival estimates were low across all 7 countries, with 1-year NS ranging from 21.1% in New Zealand to 30.9% in Australia, and 3-year NS from 6.6% in the UK to 10.9% in Australia. Most pancreatic cancers were diagnosed with distant stage, ranging from 53.9% in Ireland to 83.3% in New Zealand. While survival differences were evident between countries across all stage categories at one year after diagnosis, this survival advantage diminished, particularly in cases with distant stage. CONCLUSION: This study demonstrated the importance of stage and age at diagnosis in pancreatic cancer survival. Although progress has been made in improving pancreatic cancer prognosis, the disease is highly fatal and will remain so without major breakthroughs in the early diagnosis and management.
BACKGROUND: The global burden of pancreatic cancer has steadily increased, while the prognosis after pancreatic cancer diagnosis remains poor. This study aims to compare the stage- and age-specific pancreatic cancer net survival (NS) for seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. METHODS: The study included over 35,000 pancreatic cancer cases diagnosed during 2012-2014, followed through 31 December 2015. The stage- and age-specific NS were calculated using the Pohar-Perme estimator. RESULTS: Pancreatic cancer survival estimates were low across all 7 countries, with 1-year NS ranging from 21.1% in New Zealand to 30.9% in Australia, and 3-year NS from 6.6% in the UK to 10.9% in Australia. Most pancreatic cancers were diagnosed with distant stage, ranging from 53.9% in Ireland to 83.3% in New Zealand. While survival differences were evident between countries across all stage categories at one year after diagnosis, this survival advantage diminished, particularly in cases with distant stage. CONCLUSION: This study demonstrated the importance of stage and age at diagnosis in pancreatic cancer survival. Although progress has been made in improving pancreatic cancer prognosis, the disease is highly fatal and will remain so without major breakthroughs in the early diagnosis and management.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: G A Gooiker; V E P P Lemmens; M G Besselink; O R Busch; B A Bonsing; I Q Molenaar; R A E M Tollenaar; I H J T de Hingh; M W J M Wouters Journal: Br J Surg Date: 2014-05-20 Impact factor: 6.939
Authors: Anouk E J Latenstein; Lydia G M van der Geest; Bert A Bonsing; Bas Groot Koerkamp; Nadia Haj Mohammad; Ignace H J T de Hingh; Vincent E de Meijer; Izaak Q Molenaar; Hjalmar C van Santvoort; Geertjan van Tienhoven; Joanne Verheij; Pauline A J Vissers; Judith de Vos-Geelen; Olivier R Busch; Casper H J van Eijck; Hanneke W M van Laarhoven; Marc G Besselink; Johanna W Wilmink Journal: Eur J Cancer Date: 2019-12-13 Impact factor: 9.162
Authors: A E J Latenstein; T M Mackay; L G M van der Geest; C H J van Eijck; V E de Meijer; M W J Stommel; P A J Vissers; M G Besselink; I H J T de Hingh Journal: Br J Surg Date: 2021-07-23 Impact factor: 6.939
Authors: Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman Journal: Lancet Date: 2018-01-31 Impact factor: 79.321
Authors: Kasper Wennervaldt; Anne Mette Kejs; Henriette Lipczak; Paul Bartels; Michael Borre; Claus Wilki Fristrup; Henrik Kehlet Journal: Dan Med J Date: 2018-09 Impact factor: 1.240
Authors: Melina Arnold; Mark J Rutherford; Aude Bardot; Jacques Ferlay; Therese M-L Andersson; Tor Åge Myklebust; Hanna Tervonen; Vicky Thursfield; David Ransom; Lorraine Shack; Ryan R Woods; Donna Turner; Suzanne Leonfellner; Susan Ryan; Nathalie Saint-Jacques; Prithwish De; Carol McClure; Agnihotram V Ramanakumar; Heather Stuart-Panko; Gerda Engholm; Paul M Walsh; Christopher Jackson; Sally Vernon; Eileen Morgan; Anna Gavin; David S Morrison; Dyfed W Huws; Geoff Porter; John Butler; Heather Bryant; David C Currow; Sara Hiom; D Max Parkin; Peter Sasieni; Paul C Lambert; Bjørn Møller; Isabelle Soerjomataram; Freddie Bray Journal: Lancet Oncol Date: 2019-09-11 Impact factor: 41.316
Authors: Bradley N Reames; Alex B Blair; Robert W Krell; Vincent P Groot; Georgios Gemenetzis; James C Padussis; Sarah P Thayer; Massimo Falconi; Christopher L Wolfgang; Matthew J Weiss; Chandrakanth Are; Jin He Journal: Ann Surg Date: 2021-06-01 Impact factor: 13.787